ARS Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
ARS Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q2 2024.
  • ARS Pharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 2.66 %, a 40.4% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 2.66 -1.81 -40.4% Jun 30, 2024
Q1 2024 2.94 -5.65 -65.8% Mar 31, 2024
Q4 2023 3.47 -30 -89.6% Dec 31, 2023
Q3 2023 3.93 +37.6 Sep 30, 2023
Q2 2023 4.47 -28.3 -86.3% Jun 30, 2023
Q1 2023 8.59 -3.44 -28.6% Mar 31, 2023
Q4 2022 33.5 +26.8 +401% Dec 31, 2022
Q3 2022 -33.7 -39.8 -651% Sep 30, 2022
Q2 2022 32.7 Jun 30, 2022
Q1 2022 12 Mar 31, 2022
Q4 2021 6.68 Dec 31, 2021
Q3 2021 6.11 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.